NasdaqGM:MNKDBiotechs
How MannKind’s First Pediatric Afrezza Trial (INHALE-1ST) At MannKind (MNKD) Has Changed Its Investment Story
MannKind Corporation recently reported that it has enrolled the first pediatric patient in INHALE-1ST, a clinical study evaluating the safety and efficacy of Afrezza (insulin human) Inhalation Powder initiated soon after type 1 diabetes diagnosis in youth aged 10 and above, used alongside once-daily basal insulin.
This milestone builds on the FDA’s October 2025 acceptance of a supplemental Biologics License Application for pediatric Afrezza, positioning the inhaled insulin as a potential...